Type 2 diabetes affects hundreds of millions of people worldwide and is one of the biggest risk factors for heart disease.
Many patients eventually develop blocked arteries, heart attacks or strokes even while taking medicines to control blood sugar. Because of this, doctors are increasingly looking for treatments that improve both blood sugar and long-term heart health.
Mounjaro, known by its generic name tirzepatide, is one of the newest diabetes medicines. It works by copying the effects of natural hormones that help regulate blood sugar, slow stomach emptying and reduce appetite. Many patients also lose weight while taking the medicine, which may provide additional health benefits.
Although earlier clinical trials suggested tirzepatide was at least as safe for the heart as other modern diabetes medicines, doctors still wanted to know how well it performs in routine medical care. To answer this question, researchers carried out a large study using health insurance records from across the United States. Their findings were published in The BMJ.
The research included nearly 53,000 adults with type 2 diabetes, excess body weight and established heart disease. Participants started either tirzepatide or sitagliptin, another commonly used diabetes medicine that has little effect on cardiovascular risk. Researchers then followed patients for up to one year.
To improve the reliability of the comparison, the scientists considered many health factors including age, sex, race, body weight, previous heart conditions, other illnesses and medicines. Sophisticated statistical techniques were used to make the two groups as similar as possible before outcomes were compared.
During the first year of treatment, major cardiovascular events occurred less often among patients taking tirzepatide. About 2.9% experienced a heart attack, stroke or cardiovascular death compared with 4.4% of those receiving sitagliptin. The researchers estimated that treating 70 people with tirzepatide could prevent one major cardiovascular event.
The medicine also appeared to reduce the risk of heart attacks by about one-third. In addition, hospital admissions due to infections, infection-related deaths and deaths from any cause were all lower in the tirzepatide group. However, the risk of ischemic stroke did not differ significantly between treatments.
These findings suggest tirzepatide may provide benefits that extend beyond lowering blood sugar. Better weight control, healthier blood sugar levels and improvements in other metabolic factors may all contribute to lower cardiovascular risk, although the exact reasons still require further research.
The authors caution that the study cannot prove that tirzepatide directly caused the better outcomes because patients were not randomly assigned to treatments. The observation period was also relatively short, meaning longer-term safety and effectiveness remain uncertain.
Experts writing in an editorial alongside the study said the results are promising but several important questions remain unanswered. Future randomized trials should determine exactly where tirzepatide fits among the growing number of heart-protective diabetes medicines. Cost, insurance approval and drug availability will also influence how many patients can benefit.
Overall, the study provides encouraging real-world evidence that tirzepatide may lower the risk of serious cardiovascular events in people with type 2 diabetes and heart disease. While the results should not be viewed as final proof, they strengthen the growing evidence that modern diabetes treatments can improve both metabolic health and cardiovascular outcomes.
This study is valuable because it reflects what happens in everyday clinical practice rather than under tightly controlled trial conditions.
Its large sample size increases confidence in the findings, but observational research always carries the possibility of hidden biases. Longer randomized studies across different countries will be important before firm treatment recommendations are made.
Source: The BMJ.
